Previous 10 | Next 10 |
Cymabay Therapeutics, Inc. (CBAY) Q2 2019 Earnings Conference Call August 07, 2019, 16:30 ET Company Participants Daniel Menold - VP, Finance Sujal Shah - President, CEO & Director Charles McWherter - SVP & Chief Scientific Officer Pol Boudes - Chief Medical Officer ...
CymaBay Therapeutics (NASDAQ: CBAY ): Q2 GAAP EPS of -$0.35 beats by $0.02 . More news on: CymaBay Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEWARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the...
NEWARK, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced the addition of Ms. Janet Dorling a...
NEWARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
Introduction Intercept Pharmaceutical's ( ICPT ) Ocaliva was FDA-approved in 2016, under the accelerated approval program, for primary biliary cirrhosis [PBC], a rare disease that lacks sufficient options. Ocaliva is the second drug approved for PBC. Approved in 1997, " UDCA is effecti...
Market Assessment Clinical development of effective therapeutics for cholestatic liver diseases remained dormant for decades until recent approval of obeticholic acid (OCA) by Intercept Pharmaceuticals ( ICPT ) in 2016 for PBC. Despite clinical meaningful benefits derived from OCA, its pru...
Perspective On The Opioid Crisis Opioids are therapeutically effective at controlling pain. Unfortunately, they can equally trigger addictive behaviors when clinically misused. In the news, several mid-large cap biopharmas, privately held and publicly listed, are currently involved in "opi...
Market Assessment Eli Lilly ( LLY ) is a large-cap ($102.6B) biopharma known for innovative and diverse therapeutics for diseases affecting the endocrine system, immune system, and the brain. Its oncology products are broad with therapeutics for cancers affecting non-small cell lung, colon...
Market Assessment GlaxoSmithKline plc (GSK) is a large cap ($99B) commercial stage biopharma known for its innovative therapeutics for diverse disease states affecting many organ systems. GSK is not really a household name in reference to therapeutics for viral and non-viral liver diseases...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...